InsiderTrades.com logo
James H. Mackaness net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

James Mackaness Biography and Net Worth

CFO of Soleno Therapeutics
Mr. Mackaness has been a partner at FLG Partners, a leading Silicon Valley chief financial officer services and board advisory consultancy, since September 2019. Prior to joining FLG, Mr Mackaness served as Chief Financial Officer for Invuity, Inc (NASDAQ: IVTY) sold to Stryker Corporation. Prior to Invuity, Mr. Mackaness served as Chief Financial Officer and Chief Operating Officer of IRIDEX Corporation (NASDAQ: IRIX). Prior to that, he served as Chief Financial Officer of NextHop Technologies, Inc., a networking wireless technology company. And prior to that, he served as Chief Financial Officer of Infogear Technologies Corporation which was sold to Cisco Systems, Inc. where Mr. Mackaness held a senior management role responsible for business development. Mr. Mackaness began his career at Ernst & Young LLP. where he became an audit manager, and received his B.A. with honors in Psychology from the University of Warwick, England and is a Chartered Accountant.

What is James H. Mackaness' net worth?

The estimated net worth of James H. Mackaness is at least $6.61 million as of March 27th, 2025. Mr. Mackaness owns 105,176 shares of Soleno Therapeutics stock worth more than $6,612,415 as of April 11th. This net worth evaluation does not reflect any other investments that Mr. Mackaness may own. Learn More about James H. Mackaness' net worth.

How do I contact James H. Mackaness?

The corporate mailing address for Mr. Mackaness and other Soleno Therapeutics executives is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. Soleno Therapeutics can also be reached via phone at (650) 213-8444 and via email at ir@soleno.life. Learn More on James H. Mackaness' contact information.

Has James H. Mackaness been buying or selling shares of Soleno Therapeutics?

James H. Mackaness has not been actively trading shares of Soleno Therapeutics during the last ninety days. Most recently, James H. Mackaness sold 90,622 shares of the business's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $69.44, for a transaction totalling $6,292,791.68. Following the completion of the sale, the chief financial officer now directly owns 105,176 shares of the company's stock, valued at $7,303,421.44. Learn More on James H. Mackaness' trading history.

Who are Soleno Therapeutics' active insiders?

Soleno Therapeutics' insider roster includes Anish Bhatnagar (CEO), Patricia Hirano (Insider), Michael Huang (VP), James Mackaness (CFO), Matthew Pauls (Director), Jack Schuler (Major Shareholder), and Kristen Yen (Senior Vice President, Clinical Operations). Learn More on Soleno Therapeutics' active insiders.

Are insiders buying or selling shares of Soleno Therapeutics?

In the last twelve months, insiders at the sold shares 24 times. They sold a total of 2,510,089 shares worth more than $139,065,642.37. The most recent insider tranaction occured on April, 1st when insider Patricia C Hirano sold 3,782 shares worth more than $265,156.02. Insiders at Soleno Therapeutics own 12.3% of the company. Learn More about insider trades at Soleno Therapeutics.

Information on this page was last updated on 4/1/2025.

James H. Mackaness Insider Trading History at Soleno Therapeutics

See Full Table

James H. Mackaness Buying and Selling Activity at Soleno Therapeutics

This chart shows James H Mackaness's buying and selling at Soleno Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$5M$0$5MTotal Insider BuyingTotal Insider Selling

Soleno Therapeutics Company Overview

Soleno Therapeutics logo
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Read More

Today's Range

Now: $62.87
Low: $59.48
High: $64.64

50 Day Range

MA: $52.86
Low: $43.68
High: $73.67

2 Week Range

Now: $62.87
Low: $36.61
High: $74.00

Volume

1,337,155 shs

Average Volume

704,950 shs

Market Capitalization

$2.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A